Ribometrix has a proven track record of collaborative execution across multiple partnerships and disease indications.
Our proprietary platform enables multiple novel methodologies that target and modulate RNA biology, via direct small molecule targeting of RNA or disrupting RNA-RNA binding protein interactions.
These strategies include:
“Genentech is committed to exploring innovative approaches to drug targets that are difficult to address with conventional approaches,” said James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “Ribometrix has built capabilities to drug specific RNAs, and we look forward to a productive collaboration to explore this emerging area of science.”
“Targeting RNA is a potentially powerful new approach for developing small molecule therapeutics, and Ribometrix has developed an innovative technology for the accelerated discovery of selective candidates in this new space,” said Mark Bunnage, Senior Vice President and Site Head, Boston Research at Vertex. “This partnership adds a novel mechanism to our internal toolkit which has the potential to enhance our ongoing research capabilities and support the expansion of our pipeline of transformative medicines in serious diseases.” Ribometrix is collaborating with Vertex to discover and develop RNA-targeted small molecule therapeutics against up to three therapeutic programs.”
We employ three independent but related strategies to develop small molecule therapeutics: (1) Direct targeting of complex RNA structures, (2) disrupting RNA/RNA-binding protein interactions, and (3) targeting an RNA for degradation. We believe our commitment to this new paradigm will deliver innovative new therapies to patients.
Meet the Ribometrix team, where every individual is valued as part of a collaborative community sharing a common focus on advancing the field of modulating RNA biology to discover and develop transformative small-molecule drugs.